Global Drug Supply – Defining the New Road from Powder to the Patient
Ulrich D. Korneck1 and Michael Jarosch2
Operational Excellence Center1 and Pharmaceutical Competence Center2, Camelot Management Consultants, Mannheim (Germany)
The rise of emerging markets, increasing price pressure, and expiring patents are forcing pharmaceutical companies to change the way they operate and manage their value chains. Leaving the blockbuster business model behind, they are concentrating on their core competences and increasingly shifting product volume to thirdparty manufacturing. They have migrated into four business models: Harvesters, Rx Innovators, Gx Innovators, and Generics. These business models open up new opportunities, especially for companies that cannot rely on a strong pipeline. But regardless of the strategic focus, a stronger collaboration with third-party suppliers is vital to all of them. Steering a third-party network differs completely from managing own sites. The article describes the three phases in which pharmaceutical companies are most likely to make this change: Decision – Transfer – Stabilization.
pharmind 2011, Nr. 12, Seite 2152